• Targeting the ERα DBD-LBD Interface with Mitoxantrone: A Nov

  2026-05-12

  This study uncovers a previously unexploited vulnerability in estrogen receptor alpha (ERα), demonstrating that mitoxantrone binds the DBD-LBD interface to drive rapid receptor degradation via proteasomal pathways. The work establishes a new paradigm for DNA topoisomerase II inhibitors in overcoming resistance in breast cancer, with significant implications for research on receptor dynamics and therapeutic intervention.

• D-Luciferin Sodium Salt: Optimizing Bioluminescence in Oncol

  2026-05-12

  D-Luciferin sodium salt is the gold-standard firefly luciferase substrate, enabling ultra-sensitive, ATP-dependent bioluminescence assays for cell viability and metabolism monitoring. Discover how cutting-edge workflows, including mRNA-LNP programming of CAR macrophages, are revolutionizing bioluminescence imaging in oncology research with this robust reagent.

• Adefovir (GS-0393): Optimizing HBV Antiviral Research Workfl

  2026-05-11

  Adefovir (GS-0393) stands apart as a water-soluble, high-purity nucleotide analog for hepatitis B virus (HBV) research, offering robust DNA polymerase inhibition and precise OAT1 transporter probing. This guide details practical protocols, advanced use-cases, and troubleshooting strategies to maximize the translational reliability of your antiviral studies.

• CX-5461: RNA Polymerase I Inhibitor for Advanced Cancer Rese

  2026-05-11

  CX-5461 from APExBIO stands out as a robust, orally bioavailable RNA polymerase I inhibitor, enabling precise targeting of ribosome biogenesis in cancer cells. With deep literature support and protocol-driven reliability, it empowers researchers to interrogate autophagy, senescence, and chemoresistance mechanisms in solid tumors with unprecedented clarity.

• Fluconazole: Mechanistic Benchmark for Antifungal Resistance

  2026-05-10

  Fluconazole remains the gold standard fungal cytochrome P450 enzyme 14α-demethylase inhibitor for dissecting antifungal resistance mechanisms in vitro and in vivo. This article details advanced experimental workflows, troubleshooting insights, and evidence-driven protocol refinements that maximize the reliability and translational value of Fluconazole in fungal pathogenesis research.

• Amorolfine Hydrochloride: Applied Antifungal Workflows & Ins

  2026-05-09

  Amorolfine Hydrochloride unlocks advanced antifungal research by enabling precise membrane disruption assays and novel ploidy stress investigations. This guide translates bench protocols and reference breakthroughs into actionable, data-backed workflows for scientists dissecting fungal cell integrity and antifungal resistance.

• Mitochondrial ROS-Linked Apoptosis and Muscle Atrophy in Ova

  2026-05-09

  This study investigates the role of mitochondrial reactive oxygen species (ROS) in driving apoptosis and necroptosis during muscle atrophy in metastatic ovarian cancer. By targeting mitochondrial ROS with SkQ1, the authors reveal that suppressing apoptotic caspase activity does not prevent muscle atrophy, challenging prevailing assumptions about cell death pathways in cancer cachexia.

• MMP7 Drives EMT and Liver Fibrosis via E-cadherin/β-Catenin

  2026-05-08

  This study uncovers how matrix metalloproteinase 7 (MMP7) promotes liver fibrosis in biliary atresia (BA) by inducing epithelial–mesenchymal transition (EMT) through the E-cadherin/β-catenin signaling pathway. The findings offer mechanistic insights and highlight the therapeutic potential of directly targeting MMP7 or downstream β-catenin activity in fibrotic liver disease.

• Amphotericin B: Applied Protocols for Fungal Infection Resea

  2026-05-07

  Leverage Amphotericin B’s potent antifungal activity for robust cell-based and mechanistic assays. This guide details experimental workflows, troubleshooting strategies, and protocol enhancements, enabling reproducible and insightful outcomes in fungal infection research.

• Azithromycin: Mechanistic Advances and Translational Impact

  2026-05-07

  This article delivers a strategic, evidence-based perspective on the use of Azithromycin—a potent macrolide antibiotic—in bacterial infection research and trypanosomosis models. We bridge mechanistic insight with actionable experimental guidance, contextualize APExBIO’s offering within the competitive landscape, and provide protocol benchmarks, translational context, and a forward-looking outlook for translational researchers.

• Tomentodione M Reverses Docetaxel Resistance via P-gp/p38 MA

  2026-05-06

  This study demonstrates that tomentodione M, a natural meroterpenoid, sensitizes multidrug-resistant cancer cells to chemotherapeutic agents such as Docetaxel by downregulating P-glycoprotein through inhibition of p38 MAPK signaling. The findings offer a mechanistic rationale for targeting the P-gp/p38 MAPK axis to overcome clinical drug resistance, providing a foundation for future cancer chemotherapy research.

• Practical Guide to Oligo (dT) 25 Beads for mRNA Purification

  2026-05-06

  Oligo (dT) 25 Beads enable efficient and selective eukaryotic mRNA isolation by targeting polyA tails, supporting downstream applications such as RT-PCR and sequencing. This product is best suited for workflows requiring high-purity mRNA from total RNA or cell lysates, but is not recommended for non-polyadenylated RNA species or prokaryotic samples.

• Optimizing Bioluminescent Assays with EZ Cap™ Firefly Lucife

  2026-05-05

  Explore how Firefly Luciferase mRNA with 5-moUTP modification advances assay sensitivity, mRNA stability, and immune evasion. This article uncovers practical innovations and comparative insights beyond existing reviews.

• Mitochondrial NAD+ Deficiency Drives Aortic Aneurysm via Col

  2026-05-05

  This study identifies mitochondrial NAD+ deficiency in vascular smooth muscle as a direct driver of thoracic and abdominal aortic aneurysm through impaired collagen III turnover. Multiomics and genetic analyses reveal SLC25A51-regulated mitochondrial NAD+ homeostasis as a critical determinant of proline biosynthesis and aortic wall stability, providing new mechanistic insight and highlighting potential molecular targets for future therapeutic strategies.

• (S)-(+)-Ibuprofen: Advanced COX Inhibitor Use in Lab Researc

  2026-05-04

  (S)-(+)-Ibuprofen offers high selectivity and reproducibility for inflammation pathway research, outperforming racemic mixtures in precision and tolerability. This guide translates cutting-edge findings into actionable protocols, troubleshooting insights, and advanced applications, empowering researchers to achieve robust, reproducible results in both in vitro and in vivo settings.

16388 records 3/1093 page Previous Next 12345 下5页 Last page